Publications by authors named "Suzanne Lentzsch"

89Publications

Targeting GCK pathway: a novel and selective therapeutic strategy against RAS mutated multiple myeloma.

Blood 2020 Oct 9. Epub 2020 Oct 9.

Columbia University Medical Center, New York, New York, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020006334DOI Listing
October 2020

Prognostic impact of t(11;14) in multiple myeloma: Black and white or shades of gray?

Cancer 2020 Sep 23. Epub 2020 Sep 23.

Multiple Myeloma and Amyloidosis Service, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.33206DOI Listing
September 2020

The clinical and pathological features of plasma cell myeloma post solid organ transplantation.

Am J Hematol 2020 Aug 30. Epub 2020 Aug 30.

Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, US.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25988DOI Listing
August 2020

Modern Treatments and Future Directions for Relapsed/Refractory Multiple Myeloma Patients.

Clin Lymphoma Myeloma Leuk 2020 Jul 7. Epub 2020 Jul 7.

Division of Hematology/Oncology, Columbia University Medical Center, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.06.023DOI Listing
July 2020

Emerging drugs for the treatment of light chain amyloidosis.

Expert Opin Emerg Drugs 2020 09 24;25(3):299-317. Epub 2020 Aug 24.

Department of Medicine, Division of Hematology and Oncology, Columbia University Medical Center , New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2020.1803829DOI Listing
September 2020

Diagnosis and management of systemic light chain AL amyloidosis.

Pharmacol Ther 2020 10 17;214:107612. Epub 2020 Jun 17.

Department of Internal Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York, NY, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2020.107612DOI Listing
October 2020

Nonchemotherapy Treatment of Immunoglobulin Light Chain Amyloidosis.

Acta Haematol 2020 11;143(4):373-380. Epub 2020 Jun 11.

Columbia University Medical Center, New York, New York, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507724DOI Listing
September 2020

Case Report: Carfilzomib-induced Thrombotic Microangiopathy With Complement Activation Treated Successfully With Eculizumab.

Clin Lymphoma Myeloma Leuk 2020 04 4;20(4):e155-e157. Epub 2020 Feb 4.

Division of Hematology and Oncology, Columbia University Medical Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.01.016DOI Listing
April 2020

Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma.

Blood Cancer J 2020 02 3;10(2):13. Epub 2020 Feb 3.

Division of Hematology/Oncology, Columbia University Irving Medical Center, 161 Fort Washington Ave, New York, NY, 10032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0278-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997347PMC
February 2020

How I treat a refractory myeloma patient who is not eligible for a clinical trial.

Hematology Am Soc Hematol Educ Program 2019 12;2019(1):125-136

Columbia University Vagelos College of Physicians and Surgeons, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/hematology.2019000016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913488PMC
December 2019

Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?

Clin Lymphoma Myeloma Leuk 2019 10 15;19(10):686-688. Epub 2019 Jul 15.

Division of Hematology/Oncology, Columbia University Medical Center, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.07.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954683PMC
October 2019

Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.

Clin Lymphoma Myeloma Leuk 2019 09 1;19(9):555-559. Epub 2019 Apr 1.

Department of Internal Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.03.029DOI Listing
September 2019

Targeting transcription factors in multiple myeloma: evolving therapeutic strategies.

Expert Opin Investig Drugs 2019 05 16;28(5):445-462. Epub 2019 Apr 16.

b Department of Internal Medicine II , University Hospital Krems, Karl Landsteiner University of Health Sciences , Krems an der Donau , Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2019.1605354DOI Listing
May 2019

Beyond NEOD001 for systemic light-chain amyloidosis.

Blood 2018 11 21;132(18):1992-1993. Epub 2018 Sep 21.

The John Conant Davis Myeloma and Amyloid Program, Division of Hematology-Oncology, Department of Medicine, Tufts Medical Center, Boston, MA; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-07-865857DOI Listing
November 2018

Bone-Modifying Agents: Complicated to Use.

J Oncol Pract 2018 08;14(8):469-470

Columbia University Medical Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.18.00444DOI Listing
August 2018

Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation.

Haematologica 2018 10 28;103(10):1688-1697. Epub 2018 Jun 28.

Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine and Cancer Institute, PA, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.188227DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165797PMC
October 2018

Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors.

Leuk Lymphoma 2018 10 2;59(10):2465-2469. Epub 2018 Feb 2.

a Department of Medicine, College of Physicians and Surgeons , Columbia University , New York , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1429605DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072618PMC
October 2018

The Critical Role of Imaging in the Management of Multiple Myeloma.

Curr Hematol Malig Rep 2017 06;12(3):168-175

Division of Hematology/Oncology, Columbia University Medical Center, Herbert Irving Pavilion, 161 Fort Washington Ave, New York, NY, 10032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-017-0379-9DOI Listing
June 2017

Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.

Ther Adv Hematol 2017 Feb 9;8(2):55-70. Epub 2016 Dec 9.

Professor of Medicine, Director, Multiple Myeloma and Amyloidosis Service, Columbia University Medical Center, Herbert Irving Pavilion, R 953, 161 Ft. Washington Ave, New York, NY 10032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620716680548DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298389PMC
February 2017

Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.

Curr Cancer Drug Targets 2017 ;17(9):846-857

Division of Hematology/Oncology, College of Physicians and Surgeons, Columbia University, New York, NY. United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009617666170214104426DOI Listing
June 2018

High-risk smoldering myeloma: Perspective on watchful monitoring.

Semin Oncol 2016 Dec 5;43(6):697-699. Epub 2016 Nov 5.

Multiple Myeloma and Amyloidosis Service, Columbia University Medical Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2016.11.001DOI Listing
December 2016

Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma.

Mol Cancer Ther 2016 04 3;15(4):711-9. Epub 2016 Mar 3.

Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0798DOI Listing
April 2016

Rapidly Progressive Transthyretin-Mediated Amyloidosis in a Domino Liver Transplant Recipient of a Ser23Asn Donor.

J Clin Neuromuscul Dis 2016 Mar;17(3):142-5

*Peripheral Neuropathy Center, Neurological Institute; Departments of †Cardiology; ‡Hematology and Oncology; and §Gastroenterology, Columbia University, College of Physicians and Surgeons, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CND.0000000000000110DOI Listing
March 2016

Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption.

Mol Carcinog 2015 Dec 16;54(12):1796-806. Epub 2015 Jan 16.

Department of Pharmaceutical Sciences and Drug Discovery Institute, Computational Chemical Genomics Screening Center, School of Pharmacy, and NIH NIDA Center of Excellence for Computational Drug Abuse Research, University of Pittsburgh, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mc.22251DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504841PMC
December 2015

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.

J Clin Oncol 2015 Feb 20;33(6):657-64. Epub 2015 Jan 20.

Meletios A. Dimopoulos and Evangelos Terpos, National and Kapodistrian University of Athens School of Medicine, Athens, Greece; Jens Hillengass and Hartmut Goldschmidt, University Hospital Heidelberg, Heidelberg, Germany; Saad Usmani, Carolinas Healthcare System, Charlotte, NC; Elena Zamagni and Michele Cavo, Bologna University School of Medicine, Bologna; Antonio Palumbo, S. Giovanni Battista Hospital, University of Turin, Turin, Italy; Suzanne Lentzsch, Columbia University College of Physicians and Surgeons, New York, NY; Faith E. Davies, Institute of Cancer Research, Sutton, United Kingdom; Noopur Raje, Massachusetts General Hospital Cancer Center; Kenneth Anderson, Dana-Farber Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA; Orhan Sezer, Memorial Sisli Hospital, Istanbul, Turkey; Sonja Zweegman, VU University Medical Center, Amsterdam; Pieter Sonneveld, Erasmus University Medical Center, Rotterdam, the Netherlands; Jatin Shah, MD Anderson Cancer Center, Houston, TX; Ashraf Badros, University of Maryland Medical Center, Baltimore, MD; Kazuyuki Shimizu, Tokai Central Hospital, Kakamigahara, Japan; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; Chor-Sang Chim, Queen Mary Hospital, University of Hong Kong, Hong Kong, Special Administrative Region; Jian Hou, Changzheng Hospital, Second Military Medical University, Shanghai, People's Republic of China; Juan José Lahuerta, Hospital Universitario 12 de Octubre, Madrid, Spain; Artur Jurczyszyn, University Hospital, Krakow, Poland; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Bart Barlogie, University of Arkansas for Medical Sciences, Little Rock, AR; G. David Roodman, Indiana University School of Medicine, Indianapolis, IN; S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; and Brian G.M. Durie, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.9961DOI Listing
February 2015

Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease.

Clin Cancer Res 2014 Dec 7;20(23):5888-97. Epub 2014 Oct 7.

Department of Medicine, College of Physicians and Surgeons of Columbia University, New York-Presbyterian Hospital, New York, New York. Division of Hematology/Oncology, College of Physicians and Surgeons of Columbia University, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1692DOI Listing
December 2014

Bendamustine: the remedy that came in from the cold.

Authors:
Suzanne Lentzsch

Blood 2014 Feb;123(7):948-50

COLUMBIA UNIVERSITY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-12-539817DOI Listing
February 2014

Pomalidomide is strongly antiangiogenic and teratogenic in relevant animal models.

Proc Natl Acad Sci U S A 2013 Dec 3;110(50):E4818. Epub 2013 Dec 3.

Vascular Biology Program, Boston Children's Hospital, Department of Ophthalmology, and Department of Surgery, Harvard Medical School, Boston, MA 02115.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1315875110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864340PMC
December 2013

Multiple myeloma: Defining the high-risk patient and determining the optimal treatment strategy.

Curr Hematol Malig Rep 2013 Dec;8(4):277-83

Columbia University Division of Hematology/Oncology, 161 Ft Washington Ave, HIP 9th Floor Room 910, New York, NY, 10032, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-013-0183-0DOI Listing
December 2013

Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.

Leuk Lymphoma 2013 Sep 28;54(9):1965-74. Epub 2013 Jan 28.

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2012.755177DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208434PMC
September 2013

The application and biology of immunomodulatory drugs (IMiDs) in cancer.

Pharmacol Ther 2012 Oct 14;136(1):56-68. Epub 2012 Jul 14.

Division of Hematology/Oncology, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY 10032, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S016372581200129
Publisher Site
http://dx.doi.org/10.1016/j.pharmthera.2012.07.004DOI Listing
October 2012

Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation.

Blood 2012 May 16;119(18):4205-14. Epub 2012 Mar 16.

Department of Medicine, Division of Hematology and Oncology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15240, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2011-05-353300DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359740PMC
May 2012

Targeting the microtubular network as a new antimyeloma strategy.

Mol Cancer Ther 2011 Oct 8;10(10):1886-96. Epub 2011 Aug 8.

Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-11-0234DOI Listing
October 2011

Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice.

J Clin Invest 2011 Jul 13;121(7):2554-69. Epub 2011 Jun 13.

Department of Medicine, Division of Hematology Oncology, Hematologic Malignancies Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213-1863, USA.

View Article

Download full-text PDF

Source
http://www.jci.org/articles/view/43706
Publisher Site
http://dx.doi.org/10.1172/JCI43706DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223821PMC
July 2011

The B lineage transcription factor E2A regulates apoptosis in chronic lymphocytic leukemia (CLL) cells.

Int Immunol 2011 Jun 6;23(6):375-84. Epub 2011 May 6.

Department of Immunology, University of Pittsburgh School of Medicine, PA 15261, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/intimm/dxr027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103389PMC
June 2011

IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.

Blood 2011 May 9;117(19):5157-65. Epub 2011 Mar 9.

Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2010-10-314278DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357942PMC
May 2011

Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3.

Cell Immunol 2011 4;268(1):37-46. Epub 2011 Feb 4.

University of Pittsburgh Cancer Institute, Department of Medicine, Division of Hematology-Oncology, Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA 15213-1863, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cellimm.2011.01.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3061826PMC
May 2011

Recent advances of IMiDs in cancer therapy.

Curr Opin Oncol 2010 Nov;22(6):579-85

Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e32833d752cDOI Listing
November 2010

Metastatic breast cancer or multiple myeloma? Camouflage by lytic lesions.

J Oncol 2010 7;2010:509530. Epub 2010 Mar 7.

Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2010/509530DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833304PMC
July 2011

Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents.

Leuk Res 2010 Jul 8;34(7):917-24. Epub 2010 Feb 8.

Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2009.12.002DOI Listing
July 2010

Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.

Blood 2010 Jan 25;115(3):605-14. Epub 2009 Nov 25.

Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2009-05-221077DOI Listing
January 2010

Paraproteinemic neuropathy.

Leuk Lymphoma 2009 Sep;50(9):1422-33

VA Pittsburgh Healthcare System, MSSL-Neurology, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190903111922DOI Listing
September 2009

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.

Mol Cancer Ther 2008 Jun;7(6):1494-505

Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, 5150 Centre Avenue, 568, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-08-0183DOI Listing
June 2008

Pathophysiology of multiple myeloma bone disease.

Hematol Oncol Clin North Am 2007 Dec;21(6):1035-49, viii

Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, and Division of Hematology/Oncology, Veterans Administration Pittsburgh Healthcare System, Research and Development, PA 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2007.08.009DOI Listing
December 2007

Treatment of multiple myeloma with SDX-308.

Drug News Perspect 2007 Sep;20(7):431-5

Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1358/dnp.2007.20.7.1149631DOI Listing
September 2007

The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.

Br J Haematol 2007 Nov;139(3):385-97

Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2007.06772.xDOI Listing
November 2007

SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma.

Arch Pharm (Weinheim) 2007 Oct;340(10):511-6

University of Pittsburgh Cancer Institute, Division of Hematology/Oncology, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ardp.200700081
Publisher Site
http://dx.doi.org/10.1002/ardp.200700081DOI Listing
October 2007

Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1.

Exp Hematol 2006 Jun;34(6):776-87

Department of Hematology, Oncology and Tumor Immunology, University Medical Center Charite, Campus Buch, Humboldt University, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2006.02.014DOI Listing
June 2006

Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.

Blood 2006 Apr 22;107(8):3098-105. Epub 2005 Dec 22.

University of Pittsburgh Cancer Institute, Division of Hematology/Oncology, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2005-08-3450DOI Listing
April 2006

Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis.

Blood 2005 May 3;105(10):3833-40. Epub 2004 Aug 3.

Department of Clinical Hematology and Clinical Diagnostics, Graduate School of Medicine, Osaka City University, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2004-03-0828DOI Listing
May 2005

Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells.

Blood 2003 May 27;101(9):3568-73. Epub 2002 Dec 27.

University Medical Center Charite, Department of Hematology, Oncology and Tumorimmunology, Robert-Rössle-Klinik, Campus Buch, Humboldt University, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2002-08-2383DOI Listing
May 2003

In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway.

Blood 2002 Nov;100(9):3311-8

Department of Hematology, Oncology, and Tumorimmunology, Robert-Rössle Cancer Center at the Max-Delbrück-Center for Molecular Medicine, Charité, Humboldt University Berlin, Campus Berlin-Buch, Linderberger Weg 80, D-13122 Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2002-01-0102DOI Listing
November 2002

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

Cancer Res 2002 Sep;62(17):4996-5000

Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
September 2002

S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.

Cancer Res 2002 Apr;62(8):2300-5

Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
April 2002